In addition, risk score was significantly and positively correlated with the immunotherapeutic hub targets (i.e., PDCD1, CTLA4, etc.), suggesting that samples with a high-risk score might be more affected by ICB pathways, then inhibited anti-tumor immune activation, and deteriorated prognosis accordingly. Here, CTLA4 is linked to neoplasm.